Summary

INdividualized Therapy FOr Relapsed Malignancies in Childhood
The INFORM-Register Study (INdividualized Therapy for Relapsed Malignancies in Childhood or Individualized Therapy for Regression of Malignant Tumors in Children) is a DKTK cross-site initiative in the field of pediatric oncology, which is expected to develop from a registry trial into an umbrella trial.  With INFORM, the possibilities of personalized medicine open up a second chance for cancer-prone children who suffer a relapse. The registry study started in January 2015 and has sequenced approximately 260 tumor samples from patients by the end of 2016.
The plan is to perform the genomic analysis of this INFORM-2 trial within the MDEB program (starting 2017).
Pediatric patients with disease relapse will be prospectively treated, according to obtained molecular information, with matching combinatorial targeted drugs. In particular, data from the analysis of ctDNA in blood plasma will be used to monitor patients during diagnosis and treatment. Tumor samples will be subjected to a comprehensive multi-platform molecular analysis that allows for the detection of several classes of genomic alterations.
A homepage, http://www.dkfz.de/de/inform provides information about the register. INFORM is coordinated by Prof. Stefan Pfister, Prof. Peter Lichter, Prof. Olaf Witt, Heidelberg, and Prof. Angelika Eggert, Berlin.
At the end of 2016 the register was extended to include Swedish and Austrian patients. The participation of other countries is being prepared.
The INFORM registry study is the basis for a subsequent clinical trial series INFORM2. The study participants are to be assigned according to their sequencing results into one of several parallel subgroups with combinations of targeted medications.